Brief: Arcutis Completes Enrollment Of Phase 1B Alopecia Areata Study Evaluating ARQ-255
05/09/2024 13:08
Sept 5 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* ARCUTIS COMPLETES ENROLLMENT OF PHASE 1B ALOPECIA AREATA
STUDY
EVALUATING ARQ-255
* ARCUTIS BIOTHERAPEUTICS INC: PHASE 1B RESULTS EXPECTED
FIRST
HALF OF 2025
Source text for Eikon: ID:nGNX91Vfg0
Further company coverage: ARQT.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4